A5034063583- Neonatal Health and Biochemistry
- Hemoglobinopathies and Related Disorders
- Public Health in Brazil
- Methemoglobinemia and Tumor Lysis Syndrome
- Healthcare Regulation
- Malaria Research and Control
- COVID-19 Clinical Research Studies
- Women's cancer prevention and management
- Maternal and Neonatal Healthcare
- Healthcare during COVID-19 Pandemic
- Mosquito-borne diseases and control
- Long-Term Effects of COVID-19
- Science and Education Research
- Pharmaceutical studies and practices
- Palliative and Oncologic Care
- Epilepsy research and treatment
- SARS-CoV-2 and COVID-19 Research
- Pharmacological Effects and Toxicity Studies
- Pharmacology and Obesity Treatment
- Leprosy Research and Treatment
- Vector-borne infectious diseases
- Education during COVID-19 pandemic
- Pediatric health and respiratory diseases
- Synthesis and bioactivity of alkaloids
- Male Reproductive Health Studies
Fundação de Medicina Tropical
2014-2025
Universidade do Estado do Amazonas
2014-2025
Faculdade Metropolitana de Manaus
2021-2023
Centro Universitário do Rio Grande do Norte
2021-2023
Doane University
2021
Cochrane
2021
Fundação Oswaldo Cruz
2021
Biblioteca Nacional de España
2021
United States National Library of Medicine
2021
University of South Florida
2020
<h3>Importance</h3> There is no specific antiviral therapy recommended for coronavirus disease 2019 (COVID-19). In vitro studies indicate that the effect of chloroquine diphosphate (CQ) requires a high concentration drug. <h3>Objective</h3> To evaluate safety and efficacy 2 CQ dosages in patients with severe COVID-19. <h3>Design, Setting, Participants</h3> This parallel, double-masked, randomized, phase IIb clinical trial 81 adult who were hospitalized acute respiratory syndrome (SARS-CoV-2)...
Steroid use for coronavirus disease 2019 (COVID-19) is based on the possible role of these drugs in mitigating inflammatory response, mainly lungs, triggered by severe acute respiratory syndrome 2 (SARS-CoV-2). This study aimed to evaluate efficacy methylprednisolone (MP) among hospitalized patients with suspected COVID-19.A parallel, double-blind, placebo-controlled, randomized, Phase IIb clinical trial was performed aged ≥18 years clinical, epidemiological, and/or radiological COVID-19 at...
Treatment of Plasmodium vivax malaria requires the clearing asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from liver (a treatment termed "radical cure"). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for radical cure P. vivax.
Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. parasitemia and hypnozoites, termed "radical cure."
To achieve malaria elimination, Brazil must implement Plasmodium vivax radical cure. We aimed to investigate the operational feasibility of point-of-care, quantitative, glucose-6-phosphate dehydrogenase (G6PD) testing followed by chloroquine plus tafenoquine or primaquine.
Summary Background There is no specific antiviral therapy recommended for the disease caused by SARS-CoV-2 (COVID-19). Recent publications have drawn attention to possible benefit of chloroquine (CQ). Our study aimed comprehensively evaluate safety and efficacy two different CQ dosages in patients with established severe COVID-19. Methods We performed a parallel, double-blinded, randomized, phase IIb clinical trial, aiming assess as adjunctive hospitalized SARS Manaus, Brazilian Amazon....
Population-based studies conducted in Latin America have shown a high proportion of asymptomatic and submicroscopic malarial infections. Considering efforts aiming at regional elimination, it is important to investigate the role this reservoir malaria transmission peri-urban areas. This study aimed estimate prevalence Plasmodium spp. gametocyte burden on symptomatic infections Brazilian Amazon. Two cross-sectional household surveys (CS) were including all inhabitants area Manaus, western...
Abstract Plasmodium vivax is the most widely distributed human malaria parasite. Previous studies have shown that circulating microparticles during P. acute attacks are indirectly associated with severity. Extracellular vesicles (EVs) therefore major components of plasma holding insights into pathological processes. Here, we demonstrate plasma-derived EVs from patients ( Pv EVs) preferentially uptaken by spleen fibroblasts h SFs) as compared to uptake healthy individuals. Moreover, this...
BackgroundPrevention of Plasmodium vivax malaria recurrence is essential for elimination in Brazil. We evaluated the real-world effectiveness an updated treatment algorithm P radical cure Brazilian Amazon.MethodsIn this non-interventional observational study, we used retrospective data from implementation a at 43 health facilities Manaus and Porto Velho, The consisted chloroquine (25 mg/kg over 3 days) point-of-care quantitative glucose-6-phosphate dehydrogenase (G6PD) testing followed by...
Plasmodium vivax is the most widely distributed human malaria parasite and responsible for large amounts of disease burden [1].The presence P. in bone marrow was first noticed late 19th century [2], examinations sternal aspirates were performed as an accessory to peripheral blood malaria, including [3].Since then, little progress has been made studying infections this tissue.One report explored accumulation dyserythropoietic cells anaemic infected patients [4].In addition, two case studies...
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzyme deficiency, prevalent in many malaria-endemic countries. G6PD-deficient individuals are susceptible to hemolysis during oxidative stress, which can occur from exposure certain medications, including 8-aminoquinolines used treat Plasmodium vivax malaria. Accordingly, access point-of-care (POC) G6PD testing Brazil critical for safe treatment of P. malaria.This study evaluated the performance semi-quantitative, POC STANDARD...
The introduction of novel short course treatment regimens for the radical cure Plasmodium vivax requires reliable point-of-care diagnosis that can identify glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. While males be identified using a qualitative diagnostic test, genetic make-up females quantitative measurement. SD Biosensor (Republic Korea) has developed handheld G6PD (STANDARD test), approximately 90% accuracy in field studies identifying individuals with intermediate or...
Abstract Background Daily primaquine-induced hemolysis is a common cause of complications during Plasmodium vivax malaria treatment in individuals with glucose 6-phosphate dehydrogenase deficiency (G6PDd). Alternative regimens balancing safety and efficacy are needed. Methods G6PDd participants P. from two sites Brazilian Amazon between 2018 2022 were randomly allocated to three study arms, which received chloroquine (CQ) day 1 3 plus: (arm-1) seven-day course primaquine (PQ) (0.5mg/kg/day),...
The presence of Plasmodium vivax malaria parasites in the human bone marrow (BM) is still controversial. However, recent data from a clinical case and experimental infections splenectomized nonhuman primates unequivocally demonstrated this tissue.In current study, we analyzed BM aspirates 7 patients during acute attack 42 days after drug treatment. RNA extracted CD71+ cell suspensions was used for sequencing transcriptomic analysis.We all infections. To provide further insights, purified...
Introduction Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaquine and tafenoquine be guided by point-of-care testing deficiency. Methods findings Data from similar clinical studies evaluating performance of STANDARD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia, India, Thailand, United Kingdom, States were pooled. was assessed a retrospective analysis on capillary venous specimens. All...
In the Brazilian Amazon, malaria infections are primarily caused by Plasmodium vivax. The only drug that kills hypnozoite form of P. vivax is primaquine, thereby preventing relapse. However, treating glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals with primaquine can lead to severe hemolysis. G6PD deficiency (G6PDd) affects approximately 400 million people worldwide, most whom live in malaria-endemic areas. Therefore, clinicians need tools easily and reliably identify G6PDd....
Point-of-care glucose-6-phosphate dehydrogenase (G6PD) testing has the potential to make use of radical treatment for vivax malaria safer and more effective. Widespread G6PD tests as part case management been limited, in due concerns regarding product usability, user training, supervision. This study seeks assess how well end users can understand Standard™ Test (SD Biosensor, Suwon, South Korea) workflow, result output, label after training. will ultimately help inform test registration...
Effective radical cure of Plasmodium vivax malaria is essential for elimination in Brazil. P. requires administration a schizonticide, such as chloroquine, plus an 8-aminoquinoline. However, 8-aminoquinolines cause hemolysis individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, requiring prior screening to exclude those at risk. Brazil pioneering the implementation tafenoquine, single-dose 8-aminoquinoline indicated patients >70% normal G6PD activity. Tafenoquine Manaus and...
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common human genetic abnormalities, and it has a significant prevalence in male population (X chromosome linked). The purpose this study was to estimate frequency impaired fasting glucose diabetes among G6PD-deficient persons Manaus, Brazil, an area Western Brazilian Amazon which malaria endemic. dehydrogenase-deficient males had more diabetes. This feature could be used as screening tool for who are unable use primaquine...
The use of primaquine (PQ) for radical treatment Plasmodium vivax in carriers G6PD deficiency (G6PDd) constitutes the main factor associated with severe haemolysis G6PDd. current study aimed to estimate incremental cost-effectiveness ratio using a rapid diagnostic test (RDT) detect G6PDd male patients P. malaria Brazilian Amazon, comparison routine indicated by Programme Malaria Control, which does not include this evaluation. A analysis estimated RDT was carried out Amazon year 2013,...
Glucose-6-phosphate dehydrogenase (G6PD) deficiency testing is not routinely performed before primaquine treatment in most
Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency greatly hinders Plasmodium vivax malaria radical cure and further elimination due to 8-aminoquinolines-associated hemolysis. Although the deleterious health effects of primaquine in G6PD deficient individuals have been known for over 50 years, testing is not routinely performed before treatment most P . endemic areas. Method/Principal findings The qualitative CareStart screening test was implemented 12 units (MTUs) municipality...